📚 ¿Beta-bloqueantes en EPOC? El estudio PACE (Fase 3) despeja dudas. Los resultados confirman que el Bisoprolol es seguro: protege el corazón sin aumentar las exacerbaciones ni empeorar la función pulmonar. 📰 Publicado en @TheLancet: https://t.co/pvHqc…
Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trial - The Lancet Respiratory Medicine https://t.co/S8wjeUGw16
RT @cpgale3: In this small trial, the cardioselective β blocker, bisoprolol, had no statistically significant impact on #cardiopulmonary ef…
In this small trial, the cardioselective β blocker, bisoprolol, had no statistically significant impact on #cardiopulmonary efficacy or safety endpoints in #COPD. The PACE multicentre, double-blind, randomised, controlled, phase 3 trial @LancetRespirMed…